GENOLUTION INC. Logo

GENOLUTION INC.

Develops molecular diagnostics and RNA interference solutions for research and IVD.

225220 | KO

Overview

Corporate Details

ISIN(s):
KR7225220003
LEI:
Country:
South Korea
Address:
서울특별시 강서구 마곡중앙8로3길 63 (주)제놀루션, 강서구

Description

Genolution Inc. is a biotechnology company specializing in molecular diagnostics (MDx) and RNA interference (RNAi). The company develops and manufactures In-Vitro Diagnostic (IVD) solutions, including automated nucleic acid extraction systems, reagents, and consumables for genetic testing and life sciences research. Its core offerings support a wide range of applications from clinical diagnostics to genomics. In parallel, Genolution provides RNAi-related products and services, such as double-stranded RNA (dsRNA) synthesis for gene expression studies and agricultural development. The company focuses on creating faster and more affordable solutions for both the diagnostics and research markets.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-03-19 00:00
[기재정정]신규시설투자등
Korean 11.0 KB
2024-03-13 00:00
주주총회소집공고
Korean 150.3 KB
2024-03-13 00:00
의결권대리행사권유참고서류
Korean 122.2 KB
2024-02-26 00:00
주주총회소집결의
Korean 17.6 KB
2024-02-26 00:00
주주총회집중일개최사유신고
Korean 4.4 KB
2024-02-15 00:00
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 11.2 KB
2024-01-09 00:00
신탁계약해지결과보고서
Korean 18.2 KB
2023-12-14 00:00
주주명부폐쇄기간또는기준일설정
Korean 4.2 KB
2023-11-14 00:00
분기보고서 (2023.09)
Korean 807.6 KB
2023-10-13 00:00
신탁계약에의한취득상황보고서
Korean 42.7 KB
2023-08-14 00:00
반기보고서 (2023.06)
Korean 753.3 KB
2023-07-10 00:00
주요사항보고서(자기주식취득신탁계약체결결정)
Korean 25.9 KB
2023-06-19 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.0 KB
2023-06-19 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.0 KB
2023-05-16 00:00
신규시설투자등
Korean 7.1 KB

Automate Your Workflow. Get a real-time feed of all GENOLUTION INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for GENOLUTION INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for GENOLUTION INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.